United States Neuroprotection Market to Reach USD 14.2 Billion by 2035 |Driven by Neurodegenerative Diseases & Stroke Incidence | North America leads (42%) | Key Players - Eli Lilly, Novartis, AstraZeneca, Daiichi Sankyo, Allergan

Leander, Texas and Tokyo, Japan - Feb.5.2026
The Neuroprotection Market Size was estimated at 5.9 USD Billion in 2024. The Neuroprotection industry is projected to grow from 7.1 USD Billion in 2025 to 14.2 USD Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 6.23% during the forecast period 2025 - 2035

The market is driven by the rising prevalence of neurodegenerative disorders and increasing incidence of stroke and traumatic brain injuries. Therapeutic approaches such as neuroprotective drugs, biologics, and regenerative therapies dominate research and adoption. Hospitals, specialty neurology clinics, and research institutions are primary end-users. Advancements in neuroscience research, growing clinical trials, and demand for disease-modifying treatments fuel market growth.

Download your exclusive sample report today: (corporate email gets priority access): https://www.datamintelligence.com/download-sample/neuroprotection-market?praveen

Neuroprotection Market: Competitive Intelligence
Eli Lilly and Company, Daiichi Sankyo Company, Allergan plc, Novartis AG, AstraZeneca plc, Dr. Reddy's Laboratories Ltd, and Astrocyte Pharmaceuticals, Inc.

The Neuroprotection Market is gaining strategic significance as the global burden of neurological disorders such as Alzheimer's disease, Parkinson's disease, stroke, multiple sclerosis, and traumatic brain injury continues to rise. Companies including Eli Lilly and Company, Daiichi Sankyo, Allergan, Novartis AG, AstraZeneca, Dr. Reddy's Laboratories, and Astrocyte Pharmaceuticals are shaping the competitive landscape by developing therapies aimed at protecting neurons, reducing neuroinflammation, and slowing disease progression. Their research spans small molecules, biologics, and novel mechanisms that target oxidative stress, mitochondrial dysfunction, excitotoxicity, and inflammatory pathways within the central nervous system.

The competitive strength of the Neuroprotection Market lies in the combination of large pharmaceutical R&D capabilities and focused biotech innovation. Eli Lilly, Novartis, AstraZeneca, and Daiichi Sankyo leverage extensive neuroscience pipelines, advanced clinical development expertise, and global commercialization infrastructure to advance neuroprotective candidates across multiple indications. Allergan contributes strong experience in neurology and central nervous system therapeutics, while Dr. Reddy's Laboratories supports the market through cost-effective development and broader patient access in emerging markets. Astrocyte Pharmaceuticals adds specialized innovation by targeting astrocyte-mediated neuroprotection and novel CNS pathways. Together, these companies reinforce the market's innovation depth, accelerate translational research, and position neuroprotection as a critical frontier in the treatment of neurodegenerative and acute neurological conditions.

Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/neuroprotection-market?praveen

Fund Raisings
✅ January 2026 - Biogen Inc. (United States)
Biogen secured strategic investment to expand its neuroprotection research programs targeting neurodegenerative diseases such as Alzheimer's, Parkinson's, and ALS. The funding supports biomarker-driven clinical trials and next-generation disease-modifying therapies.

✅ December 2025 - Denali Therapeutics (United States)
Denali raised growth capital to advance its neuroprotective pipeline focused on blood-brain barrier-penetrant therapies. The investment accelerates small-molecule and biologic candidates aimed at slowing neuronal degeneration.

✅ November 2025 - Annexon Biosciences (United States)
Annexon attracted fresh investment to strengthen its complement-mediated neuroprotection programs. The funding supports late-stage development of therapies designed to preserve synaptic function and prevent neuronal loss.

✅ October 2025 - Voyager Therapeutics (United States)
Voyager secured capital to expand its gene-therapy-based neuroprotection platform. The investment emphasizes targeted delivery to the central nervous system and long-term neuroprotective effects in rare and common neurological disorders.

✅ September 2025 - Athira Pharma (United States)
Athira Pharma raised funding to advance neuroprotective treatments addressing cognitive impairment and neurodegeneration. The investment focuses on novel mechanisms to restore neuronal signaling and improve functional outcomes.

Product Launches & Strategic Partnerships
✅ January 2026 - Biogen (United States)
Biogen advanced its neuroprotection-focused pipeline with new disease-modifying therapies targeting neurodegenerative disorders such as Alzheimer's and Parkinson's disease. The initiative emphasizes slowing neuronal damage and preserving cognitive function.

✅ December 2025 - Roche & AC Immune (Switzerland)
Roche strengthened its partnership with AC Immune to develop novel neuroprotective biologics targeting toxic protein aggregation in neurodegenerative diseases. The collaboration aims to improve long-term neurological outcomes.

✅ October 2025 - Novartis (Switzerland)
Novartis progressed clinical development of neuroprotective therapies designed to prevent neuronal loss in multiple sclerosis and other central nervous system disorders, leveraging advanced biomarkers and precision medicine approaches.

✅ August 2025 - Eli Lilly and Company (United States)
Eli Lilly expanded its neuroscience research programs with a focus on neuroprotection in Alzheimer's disease and ALS. The efforts integrate advanced imaging, biomarkers, and targeted therapeutics to preserve neuronal function.

Mergers & Acquisitions
✅ January 2026 - Biogen Inc. (United States)
Biogen acquired a clinical-stage biotech focused on neuroprotective therapies targeting neurodegenerative diseases. The acquisition strengthens Biogen's pipeline in Alzheimer's, Parkinson's, and other CNS disorders by advancing disease-modifying treatment approaches.

✅ December 2025 - Roche Holding AG (Switzerland)
Roche expanded its neuroscience portfolio through the acquisition of a neuroprotection-focused drug discovery company. The deal enhances Roche's capabilities in synaptic preservation, neuroinflammation control, and precision neurology.

✅ October 2025 - UCB Pharma (Belgium)
UCB completed a strategic acquisition of a neuroscience startup developing novel neuroprotective mechanisms for epilepsy and movement disorders. The acquisition reinforces UCB's leadership in CNS innovation and long-term neurological disease management.

Segments Covered in the Neuroprotection Market:
By Product Type
The market is segmented into Drugs & Therapeutics 60%, Dietary Supplements & Nutraceuticals 25%, and Others 15%. Drugs and therapeutics dominate due to ongoing R&D in disease-modifying treatments for neurological disorders, while nutraceuticals are gaining traction for preventive care and cognitive health support.

By Type
Types include Synthetic Neuroprotective Agents 55%, Natural Neuroprotective Compounds 35%, and Others 10%. Synthetic agents lead due to proven clinical efficacy and regulatory approvals, while natural compounds are expanding with rising interest in plant-based and antioxidant-driven neuroprotection.

By Application
Applications include Neurodegenerative Diseases 45%, Stroke & Ischemic Injury 25%, Traumatic Brain Injury (TBI) 15%, Spinal Cord Injury 10%, and Others 5%. Neurodegenerative diseases dominate as prevalence of Alzheimer's, Parkinson's, and ALS continues to rise globally.

By End-User
End-users comprise Hospitals & Neurology Clinics 50%, Research & Academic Institutes 25%, Pharmaceutical & Biotechnology Companies 15%, and Others 10%. Hospitals lead adoption for clinical treatment, while research institutions and pharma companies drive innovation and clinical trials.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=neuroprotection-market?praveen

Regional Analysis
North America - 42% Share
North America leads with around 42% share, driven by high prevalence of neurodegenerative disorders, strong neuroscience research funding, and advanced healthcare infrastructure. The U.S. dominates with extensive R&D activity in Alzheimer's disease, Parkinson's disease, stroke, and traumatic brain injury, along with rapid adoption of novel neuroprotective therapies.

Europe - 30% Share
Europe accounts for approximately 30% share, supported by aging populations, robust academic research, and government-backed neuroscience initiatives. Germany, the UK, France, Italy, and Spain are key markets, with increasing focus on early intervention and disease-modifying treatments.

Asia Pacific - 18% Share
Asia Pacific holds nearly 18% share due to rising incidence of neurological disorders, growing healthcare investments, and improving diagnostic capabilities. Japan, China, South Korea, and India are expanding research and clinical adoption of neuroprotective drugs and therapies.

Latin America - 6% Share
Latin America represents about 6% share, fueled by increasing awareness of neurological diseases and gradual improvements in healthcare access. Brazil, Mexico, and Argentina are emerging markets for neuroprotective treatments and clinical research.

Middle East & Africa - 4% Share
Middle East & Africa holds around 4% share, with growth supported by improving healthcare infrastructure and rising focus on neurological care. GCC countries, South Africa, and Egypt are gradually investing in neurology research and treatment capabilities.

Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription?praveen

✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.